Skip to main content
NewsPublications

Scientific articles in 2022

Scientific articles in 2022

In 2022 ADx will continue to collaborate with its research partners to provide new and groundbreaking scientific research. A list of all published articles in 2022 can be found below. Make sure to check in once and a while, this list will be updated regularly.

1. Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults

Pierre-François MeyerNicholas J AshtonThomas K KarikariCherie Strikwerda-BrownTheresa KöbeJulie GonneaudAlexa Pichet BinetteHazal OzlenYara YakoubJoel SimrénJosef PanneeJuan Lantero-RodriguezAnne LabontéSuzanne L BakerMichael SchöllEugeen VanmechelenJohn C S BreitnerHenrik ZetterbergKaj BlennowJudes PoirierSylvia VilleneuvePresymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group
Ann Neurol. 2022 Jan 27. doi: 10.1002/ana.26308.

2. Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET

Cécile Tissot, Joseph Therriault, Peter Kunach, Andréa L Benedet, Tharick A. Pascoal, Nicholas J. Ashton, Thomas K. Karikari, Stijn Servaes, Firoza Z. Lussier, Mira Chamoun, Dana L. Tudorascu, Jenna Stevenson, Nesrine Rahmouni, Nina Margherita Poltronetti, Vanessa Pallen, Gleb Bezgin, Min Su Kang, Sulantha S. Mathotaarachchi, Yi-Ting Wang, Jaime Fernandez Arias, Pamela Cristina Lukasewicz Ferreira, João Pedro Ferrari-Souza, Eugeen Vanmechelen, Kaj Blennow, Henrik Zetterberg, Serge Gauthier, Pedro Rosa-Neto
eBioMedicine, Volume 76, 103837. 2022 Feb 05. doi: https://doi.org/10.1016/j.ebiom.2022.103837

3. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease

Nicholas J. Ashton, Andréa L. Benedet, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero-Rodriguez, Wagner S. Brum, Sulantha Mathotaarachchi, Joseph Therriault, Melissa Savard, Mira Chamoun, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Serge Gauthier, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow, Pedro Rosa-Neto
eBioMedicine, Volume 76, 103836. 2022 Feb 11. doi: https://doi.org/10.1016/j.ebiom.2022.103836

4. Plasma p-tau181/Aβ1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ1-42 and future cognitive decline

Christopher James FowlerErik StoopsStephanie Rainey-SmithEugeen VanmechelenJeroen VanbrabantNele DewitKimberley MaurooPaul MaruffChristopher C RoweJurgen FrippQiao-Xin LiPierrick BourgeatSteven J CollinsRalph N MartinsColin L MastersJames D Doecke
medRxiv, 22272320. 2022 Mar 13. doi: doi.org/10.1002/dad2.12375

5. Comparative analysis of total alpha-Synuclein (αSYN) immunoassays reveals that they do not capture the diversity of modified αSYN proteoforms

Lara PetriccaNour ChikiLayane Hanna-El-DaherLorène AeschbachRitwik BuraiErik StoopsMohamed-Bilal FaresHilal A Lashuel
Journal of Parkinson’s Disease, vol. Pre-press, no. Pre-press, pp 1-14, 35527570. 2022 May 2. doi:
 10.3233/JPD-223285

6. Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer’s disease

Steffi De Meyer, Jeroen Vanbrabant, Jolien M. Schaeverbeke, Mariska Reinartz, Emma S. Luckett, Patrick Dupont, Koen Van Laere, Erik Stoops, Eugeen Vanmechelen, Koen Poesen, Rik Vandenberghe
Annals of Clinical and Translational Neurology 2022; 9(5): 734–746. 2022 May 3. doi:
10.1002/acn3.51553

 7. Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease

Przemysław R KacFernando Gonzalez-OrtizJoel SimrénNele DewitEugeen VanmechelenHenrik ZetterbergKaj BlennowNicholas J AshtonThomas K Karikari
Alzheimer’s research and therapy, 14(1):65,
35545792. 2022 May 11. doi: 10.1186/s13195-022-01011-w

8. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia

Elisabeth H. Thijssen, Inge M.W. Verberk, Jana Kindermans, Adlin Abramian, Jeroen Vanbrabant, Andrew J. Ball, Yolande Pijnenburg, Afina W. Lemstra, Wiesje M. van der Flier, Erik Stoops, Christophe Hirtz, Charlotte E. Teunissen
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 14:e12285. 2022 May 15. doi:
https://doi.org/10.1002/dad2.12285

9. A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration

10. Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE)

11. P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles

12. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease